Klaus Podar - Cell Biology

Author Information

Klaus Podar is a prominent researcher affiliated with the Department of Medical Oncology at the National Center for Tumor Diseases (NCT), University of Heidelberg, located in Heidelberg, Germany. His work primarily focuses on the field of oncology, with a significant emphasis on multiple myeloma, a type of blood cancer. Through his research, he contributes to the advancement of therapeutic strategies and understanding of the pathophysiology of this disease.

Research Contributions

Klaus Podar has made substantial contributions to the field of cell biology, particularly in the study of multiple myeloma. His recent publications highlight his involvement in research on pathway-directed therapies, the role of specific transcription factors like JunB in bone marrow angiogenesis, and the evaluation of immune responses to COVID-19 vaccines in cancer patients. His work also delves into quality of life assessments for myeloma patients and the molecular mechanisms underlying cancer-related cachexia. Podar’s research is instrumental in developing innovative treatment strategies for multiple myeloma, as evidenced by his exploration of CDK9-regulated molecular events and the synergistic effects of targeting transcriptional programs.

Aliases

Klaus Podar is also known by the aliases K Podar and K. Podar. These variations of his name are used interchangeably in academic publications and citations.

Publication and Citation Metrics

Metric	Value
Total Papers	325
Citation Count	17,405
H-index	75

Publications:

Pathway-Directed Therapy in Multiple Myeloma

DOI: 10.3390/cancers13071668

Year: 2021

Publisher Correction: JunB is a key regulator of multiple myeloma bone marrow angiogenesis

DOI: 10.1038/s41375-021-01367-2

Year: 2021

Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients

DOI: 10.3390/cancers13174312

Year: 2021

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

DOI: 10.1186/s12885-021-08453-9

Year: 2021

P-082: Delineating CDK9- regulated molecular events for the development of rationally derived multiple myeloma treatment strategies

DOI: 10.1016/s2152-2650(21)02216-3

Year: 2021

The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology

DOI: 10.3390/cancers13102326

Year: 2021

Effect of cachexia on bone turnover in cancer patients: a case-control study

DOI: 10.1186/s12885-021-08518-9

Year: 2021

OAB-030: Combined targeting of distinct c-Myc and JunB transcriptional programs induces synergistic anti-myeloma activity

DOI: 10.1016/s2152-2650(21)02104-2

Year: 2021

Delineating CDK9 Regulated Molecular Events for the Development of Rationally Derived Multiple Myeloma Treatment Strategies

DOI: 10.1182/blood-2021-149254

Year: 2021

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

DOI: 10.1182/blood-2021-150311

Year: 2021

How Does PARP Function in DNA Repair?

What are Receptors?

How Are Ion Channel Receptors Regulated?

What are Recent Advances in Cell Biology?

Can DNA Fragmentation be Repaired?

How are Cells Cultured?

What Is the Impact of Aging on Tissue Homeostasis?

Is Necrosis Treatable?

What is Cryo Electron Microscopy?

How is Alpha Synuclein Linked to Parkinsonâs Disease?

Partnered Content Networks

Relevant Topics